Anthropic had one of its busiest weeks of the year between October 26 and 28, 2026 — filing to go public, reporting early results from putting Claude to work on drug discovery, and expanding two separate programs with government and scientific institutions, all within 48 hours of each other.
The IPO Filing: Ticker ANT, $16.3 Billion in Revenue, an $80.7 Billion Loss
On October 26, Anthropic filed a public Form S-1 with the SEC, signaling plans to list on the Nasdaq Global Select Market under the ticker ANT. The filing reports $16.3 billion in revenue for the first six months of 2026 — up from $1.2 billion in the same period a year earlier, and already well past the $4.6 billion the company booked for all of 2025 — against a net loss of $80.7 billion for the same six months, a gap that reflects how much Anthropic is still spending on compute and model training relative to what it’s bringing in. The filing itself leaves the share count and price range blank, which is normal at this stage; press reporting has pointed to a possible debut around the week of November 16, with investor chatter circling a valuation somewhere between $1.5 and $2 trillion, up sharply from the $965 billion mark set by its Series H round in May. None of those numbers are locked in until pricing actually happens, but the filing itself — revenue, losses, and all — is now public record.
Claude Gets Put to Work on Drug Discovery
A day later, on October 27, Anthropic published early results from six real-world drug development partnerships using Claude, including Enveda Biosciences, Generate Biomedicines, Divergence Labs, and BigHat Biosciences. The numbers are self-reported by the partner companies and describe early, mostly preclinical work — not approved drugs — but they’re specific: Divergence Labs says Claude generated roughly 35,000 candidate antibody designs for a food-allergy research program in about a month, Enveda reported an 89% cut in the time needed to review manufacturing documentation, and one partner described a CAR T-cell therapy design that came out roughly 70% shorter than a standard version in early lab testing. Anthropic says it plans to extend the work toward actual clinical trials, which is a meaningfully higher bar than anything reported so far.
Two Quieter Expansions, Same Week
The same 48 hours also brought two lower-profile announcements that fit the same pattern of Anthropic pushing Claude into institutions rather than just consumer chat. On October 27, the company expanded its partnership with the US General Services Administration to bring Claude to all levels of government, with a reported 40% discount for government partners. On October 28, its “AI for Science” program grew to cover 20 scientific foundations, institutions, and research groups, up from a smaller initial cohort. Neither is as dramatic as an IPO filing or a drug-discovery result, but both point the same direction: Anthropic positioning Claude as infrastructure for institutions with long procurement cycles, not just a product people subscribe to individually.
Why the Timing Matters
None of these four announcements needed to land in the same week, and Anthropic hasn’t explained why they did. But taken together, they’re a clearer snapshot of the company’s actual pitch to public investors than the S-1 filing alone: real revenue growing fast, real losses just as large, and a growing list of institutional customers — governments, research institutions, and now drug developers — meant to be the evidence that the revenue keeps growing after the IPO roadshow ends.
